223 related articles for article (PubMed ID: 19996290)
21. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
Lopes L; Fletcher K; Ikeda Y; Collins M
Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731
[TBL] [Abstract][Full Text] [Related]
22. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
[TBL] [Abstract][Full Text] [Related]
23. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
24. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
[TBL] [Abstract][Full Text] [Related]
25. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
[TBL] [Abstract][Full Text] [Related]
26. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
[TBL] [Abstract][Full Text] [Related]
27. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.
Giannoni F; Hardee CL; Wherley J; Gschweng E; Senadheera S; Kaufman ML; Chan R; Bahner I; Gersuk V; Wang X; Gjertson D; Baltimore D; Witte ON; Economou JS; Ribas A; Kohn DB
Mol Ther; 2013 May; 21(5):1044-54. PubMed ID: 23380815
[TBL] [Abstract][Full Text] [Related]
28. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
29. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
31. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
[TBL] [Abstract][Full Text] [Related]
32. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
[TBL] [Abstract][Full Text] [Related]
33. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
34. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
35. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
36. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
37. Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.
Babad J; Mukherjee G; Follenzi A; Ali R; Roep BO; Shultz LD; Santamaria P; Yang OO; Goldstein H; Greiner DL; DiLorenzo TP
Clin Exp Immunol; 2015 Mar; 179(3):398-413. PubMed ID: 25302633
[TBL] [Abstract][Full Text] [Related]
38. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
Johnson LA; Heemskerk B; Powell DJ; Cohen CJ; Morgan RA; Dudley ME; Robbins PF; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6548-59. PubMed ID: 17056587
[TBL] [Abstract][Full Text] [Related]
39. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
[TBL] [Abstract][Full Text] [Related]
40. TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features.
Simon S; Wu Z; Cruard J; Vignard V; Fortun A; Khammari A; Dreno B; Lang F; Rulli SJ; Labarriere N
Front Immunol; 2018; 9():1962. PubMed ID: 30214446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
